EIM
RPRX icon

Essex Investment Management’s Royalty Pharma RPRX Stock Holding History

Essex Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-962
Closed -$42K – 462
2021
Q1 		$42K Buy
+962
New +$45.6K 0.01% 376
2020
Q4 		– Sell
-995
Closed -$42K – 510
2020
Q3 		$42K Sell
995
-5
-0.5% -$215 0.01% 392
2020
Q2 		$49K Buy
+1,000
New +$49.5K 0.01% 349

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Essex Investment Management's RPRX Position: Q2 2021 in Review

Essex Investment Management sold out of Royalty Pharma (RPRX) in Q2 2021, closing a stake of 962 shares — an estimated $42K sold.

Essex Investment Management first reported a position in RPRX in Q2 2020 and held it in 3 quarters. The position peaked at $49K in Q2 2020. 236 funds tracked by Wall St. Rank hold RPRX as of Q2 2021.

  • Essex Investment Management reported no remaining Royalty Pharma position as of Q2 2021 after selling out during the quarter.
  • Essex Investment Management sold 962 Royalty Pharma shares in Q2 2021, an estimated $42K.
  • Essex Investment Management first reported a position in Royalty Pharma in Q2 2020 and held it in 3 quarters.
  • Essex Investment Management's Royalty Pharma position peaked at $49K in Q2 2020.
  • 236 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2021.

Based on Essex Investment Management's 13F filing for Q2 2021, filed 12 Aug 2021.